skip to main content

Press Releases Archive

July 27, 2020

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006

Download
July 22, 2020

Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference

Download
May 14, 2020

Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights

Download
April 29, 2020

Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting

Download
March 31, 2020

Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimer’s and Parkinson’s Therapies

Download
March 26, 2020

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Download
March 24, 2020

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation

Download
March 3, 2020

Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations

Download

You are now leaving prevailtherapeutics.com

You've clicked on a link for a third-party site, which Prevail Therapeutics does not control, influence, or endorse. Prevail is not responsible for any content on this third-party site, including the privacy policy. Click "Continue" to leave or "Go Back" to return to prevailtherapeutics.com

Continue
Top